X4 PHARMACEUTICALS, INC (XFOR) Current Ratio
- Current ratio · latest quarter: Value 11.30×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 11.30× | Current assets / current liabilities. $218.85M ÷ $19.37M ≈ 11.30× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 218.85M USD | Assets, Current |
| Current obligations | 19.37M USD | Liabilities, Current |
| Cash and equivalents | 195.09M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 2.05M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | Inventory, Net |
| Payables | 3.93M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $218.85M | $19.37M | $195.09M | (m) | $2.05M | (m) | $3.93M | (m) | 11.30× |
| 2026-03-31 | $241.98M | $23.77M | $216.91M | (m) | $1.11M | (m) | $5.07M | (m) | 10.18× |
| 2025-12-31 | $261.58M | $25.76M | $217.05M | (m) | $573.00K | (m) | $5.70M | (m) | 10.16× |
| 2025-09-30 | $132.81M | $23.51M | $69.63M | (m) | $891.00K | (m) | $5.05M | (m) | 5.65× |
| 2025-06-30 | $72.94M | $22.90M | $39.22M | (m) | $1.15M | (m) | $7.71M | (m) | 3.19× |
| 2025-03-31 | $95.70M | $25.88M | $40.26M | (m) | $509.00K | (m) | $11.12M | (m) | 3.70× |
| 2024-12-31 | $112.17M | $32.88M | $55.70M | (m) | $1.07M | (m) | $8.62M | (m) | 3.41× |
| 2024-09-30 | $142.97M | $29.26M | $97.41M | (m) | $0.00 | (m) | $8.58M | (m) | 4.89× |
| 2024-06-30 | $175.42M | $28.90M | $147.22M | (m) | $0.00 | (m) | $7.99M | (m) | 6.07× |
| 2024-03-31 | $87.33M | $23.54M | $60.49M | (m) | (m) | (m) | $8.94M | (m) | 3.71× |
| 2023-12-31 | $122.08M | $22.86M | $99.22M | (m) | $0.00 | $0.00 | $8.95M | (m) | 5.34× |
| 2023-09-30 | $147.87M | $25.43M | $131.58M | (m) | (m) | (m) | $8.13M | $0.00 | 5.81× |
| 2023-06-30 | $147.65M | $22.25M | $136.43M | (m) | (m) | (m) | $5.11M | $764.00K | 6.64× |
| 2023-03-31 | $98.22M | $19.48M | $93.41M | (m) | (m) | (m) | $5.99M | $554.00K | 5.04× |
| 2022-12-31 | $128.68M | $22.32M | $121.72M | (m) | (m) | (m) | $7.78M | $1.31M | 5.76× |
| 2022-09-30 | $85.72M | $28.71M | $79.86M | (m) | (m) | (m) | $3.80M | $14.62M | 2.99× |
| 2022-06-30 | $52.59M | $22.00M | $47.38M | (m) | (m) | (m) | $3.68M | $8.61M | 2.39× |
| 2022-03-31 | $70.88M | $14.97M | $66.43M | (m) | (m) | (m) | $3.57M | $3.42M | 4.73× |
| 2021-12-31 | $87.88M | $14.02M | $81.79M | (m) | (m) | (m) | $4.28M | $795.00K | 6.27× |
| 2021-09-30 | $80.70M | $13.23M | $76.39M | (m) | (m) | (m) | $2.42M | $693.00K | 6.10× |
| 2021-06-30 | $101.37M | $13.12M | $95.16M | (m) | (m) | (m) | $2.53M | (m) | 7.73× |
| 2021-03-31 | $119.96M | $14.67M | $114.94M | (m) | (m) | (m) | $3.09M | (m) | 8.18× |
| 2020-12-31 | $83.31M | $11.95M | $78.71M | (m) | (m) | (m) | $3.14M | $0.00 | 6.97× |
| 2020-09-30 | $93.91M | $13.18M | $88.81M | (m) | (m) | (m) | $3.89M | (m) | 7.13× |
| 2020-06-30 | $109.89M | $10.78M | $103.74M | (m) | (m) | (m) | $1.84M | (m) | 10.19× |
| 2020-03-31 | $121.95M | $7.95M | $115.05M | (m) | $3.00M | (m) | $1.25M | (m) | 15.34× |
| 2019-12-31 | $129.28M | $9.45M | $126.18M | (m) | (m) | (m) | $2.09M | (m) | 13.68× |
| 2019-09-30 | $79.22M | $8.28M | $76.25M | (m) | (m) | (m) | $1.70M | $0.00 | 9.57× |
| 2019-06-30 | $96.65M | $13.20M | $90.18M | (m) | (m) | (m) | $3.10M | $4.15M | 7.32× |
| 2019-03-31 | $26.22M | $16.45M | $22.30M | (m) | (m) | (m) | $6.13M | $5.30M | 1.59× |
| 2018-12-31 | $9.34M | $7.91M | $8.13M | (m) | (m) | (m) | $2.97M | $1.69M | 1.18× |
| 2018-09-30 | $44.93M | $8.85M | $40.75M | (m) | (m) | (m) | $2.13M | (m) | 5.08× |
| 2018-06-30 | $56.56M | $10.21M | $49.94M | (m) | (m) | (m) | $2.14M | (m) | 5.54× |
| 2018-03-31 | $68.53M | $9.30M | $64.00M | (m) | (m) | (m) | $1.11M | (m) | 7.37× |
| 2017-12-31 | $79.53M | $10.68M | $76.79M | (m) | (m) | (m) | $1.89M | (m) | 7.45× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |